Detalles de la búsqueda
1.
Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
Br J Cancer
; 115(9): 1069-1077, 2016 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27673365
2.
A novel combination treatment for fragile X syndrome predicted using computational methods.
Brain Commun
; 6(1): fcad353, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38226317
3.
The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
Cancer Sci
; 103(3): 522-7, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22181674
4.
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Blood
; 116(12): 2089-95, 2010 Sep 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-20548094
5.
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
Mol Cancer Ther
; 20(10): 1757-1768, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34330842
6.
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.
J Med Chem
; 64(7): 4071-4088, 2021 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33761253
7.
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Br J Haematol
; 150(1): 46-57, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20507304
8.
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Mol Cancer Ther
; 8(2): 324-32, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19174555
9.
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
Mol Cancer Ther
; 17(7): 1381-1391, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29695633
10.
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).
J Med Chem
; 61(16): 7314-7329, 2018 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30091600
11.
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
J Med Chem
; 61(11): 4978-4992, 2018 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29775310
12.
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Mol Cancer Ther
; 16(6): 1010-1020, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28341788
13.
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
Mol Cancer Ther
; 13(12): 2793-2804, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25349308
14.
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Mol Cancer Ther
; 11(8): 1799-808, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22714264
15.
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Clin Cancer Res
; 18(14): 3912-23, 2012 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22781553
16.
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Mol Cancer Ther
; 10(2): 360-71, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21191045
17.
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.
Mol Cancer Ther
; 10(9): 1542-52, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21764904
18.
AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Mol Cancer Ther
; 9(4): 920-8, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20354122
19.
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.
Mol Cancer Ther
; 9(5): 1100-10, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20423992
Resultados
1 -
19
de 19
1
Próxima >
>>